“We are strengthening our
James Shannon, MD, Chair of the SAB, has served on ProQR’s Supervisory Board since 2016. Most recently he was Chief Medical Officer at GlaxoSmithKline until his retirement in 2015. Mike Cheetham, PhD, is a Professor of Molecular Cell Biology at the University College London Institute of Ophthalmology. The research in the Cheetham lab is focused on understanding the molecular basis of inherited retinal diseases, developing therapies and the development of 3D retinal organoids.
- Thaddeus (Ted) Drija, MD is the former Global Head of
Ophthalmology Researchat Novartis. He is Professor of Ophthalmology at Harvard Medical Schooland an Associate Director of Eye Pathology at the Massachusetts Eye and Ear Infirmary.
S. Fong, MD, MPH, is Chief of Ophthalmology and Director of the Kaiser Permanente Southern California Eye Monitoring Center. He is also Clinical Professor of Ophthalmology at University of California, Los Angeles(UCLA) School of Medicine. Art Levin, PhD is the Chief Scientific Officer at Avidity Biosciences and has more than two decades of experience in RNA drug development from discovery through drug registration, including the development and registration of the first and only oligonucleotide medicine in ophthalmology, Vitravene. Martin Maier, PhD is Vice President Research at Alnylam Pharmaceuticals where he heads the RNAi Discovery group. Through his position at Alnylam and a prior position at Ionis Pharmaceuticals he has more than 20 years of experience in the RNA field. Tim Stout, MD, PhD, MBA is an Inherited Retinal Disease specialist and the Sid W. Richardson Professor and Margarett Root Brown Chairof the Department of Ophthalmology, and Director of the Cullen Eye Instituteat Baylor College of Medicine. Phil ZamorePhD is a Howard Hughes Medical Institute Investigator, Gretchen Stone Cook Chairof Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Chair of the RNA Therapeutics Instituteat the University of Massachusetts Medical School. He is also a co-founder of Alnylam Pharmaceuticals and Voyager Therapeutics.
Biographies for the
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such statements include, but are not limited to, statements regarding our
LifeSci Public Relations
T: +1 646 876 4933
Source: ProQR Therapeutics N.V.